Immunogenicity of GamTBvac components in GamTBvac-prime/boost and BCG-prime/GamTBvac-boost regimens.

<p>The popliteal lymph node <b>(A, C)</b> and spleen <b>(B, D)</b> cells (0.5–8×10⁵/well) of the vaccinated mice were stimulated with DBD-Ag85A (10 μg/ml; <b>A, B</b>), DBD-ESAT6-CFP10 (10 μg/ml; <b>C, D</b>) separately <i>in vitro</i> and number of IFNγ secreting cells was assessed by ELISPOT. To estimate the lymphoproliferative potential of vaccine components, the popliteal lymph node cells of the vaccinated mice (2–4×10⁵ cells/well) were stimulated with DBD-Ag85A (10 μg/ml), DBD-ESAT6-CFP10 (10 μg/ml) or PBS separately <i>in vitro</i> (<b>E)</b> five weeks after the final immunization with specific antigen composition. Total IFNγ secretion in splenocytes upon different vaccination regimens was estimated by ELISA <b>(F)</b>. To evaluate the antigen-specific antibody titer, sera were collected from each mouse one week after last immunization. Endpoint IgG titers specific to ESAT6, CFP10 and Ag85a were detected by ELISA. Sera from mice treated with PBS or adjuvant (without antigen) were used as a negative control <b>(G)</b>. Results were presented as group means ± 95%CIs, n = 4, * P<0.05, ** P<0.01. In graphs F and C asterisk indicate significant differences compare to both PBS and BCG groups.